Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ASSEMBLY BIOSCIENCES, INC.ASMB · Entity 5216 | Chief Financial Officer | July 25, 2022 | July 26, 2022 |
| Unity Biotechnology, Inc.UBX · Entity 77428 | Director | June 21, 2024 | June 21, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ASSEMBLY BIOSCIENCES, INC.
Report date July 25, 2022 · Filed July 26, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 77,228 |
Reported balance
After 2022-07-25 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2022-07-25 · Sale · Disposed 2,020 · Balance 77,228 F1: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person and represents shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.14 to $2.25, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within. F3: Includes 2,500 shares acquired under the Assembly Biosciences, Inc. Amended and Restated 2018 Employee Stock Purchase Plan on May 13, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person and represents shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.14 to $2.25, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within.
F3: Includes 2,500 shares acquired under the Assembly Biosciences, Inc. Amended and Restated 2018 Employee Stock Purchase Plan on May 13, 2022.
Unity Biotechnology, Inc.
Report date June 21, 2024 · Filed June 21, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.38 · Expires 2034-06-20 | Direct | 10,000 |
Reported balance
After 2024-06-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-06-21 · Grant · Acquired 10,000 · Balance 10,000 F1: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the one-year anniversary measured from June 21, 2024 or (ii) the date of the 2025 Annual Meeting of the Issuer's stockholders, assuming continuous service as a Director until such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the one-year anniversary measured from June 21, 2024 or (ii) the date of the 2025 Annual Meeting of the Issuer's stockholders, assuming continuous service as a Director until such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 21, 2024 Filed Jun 21, 2024 16:30 UTC | Unity Biotechnology, Inc. UBX · Entity 77428 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $1.38 | $0.00 |
DisclosureSEC source: 0000950170-24-076284 · ownership.xml · derivative · entry 1 Samar Michael P. · CIK 0001775910 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2034-06-20 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the one-year anniversary measured from June 21, 2024 or (ii) the date of the 2025 Annual Meeting of the Issuer's stockholders, assuming continuous service as a Director until such vesting date. Read SEC document |
| June 23, 2023 Filed Jun 26, 2023 17:06 UTC | Unity Biotechnology, Inc. UBX · Entity 77428 | GrantStock Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $3.25 | $0.00 |
DisclosureSEC source: 0000899243-23-016499 · doc4.xml · derivative · entry 1 Samar Michael P. · CIK 0001775910 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2033-06-22 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the one-year anniversary measured from June 23, 2023 or (ii) the date of the 2024 Annual Meeting of the Issuer's stockholders, assuming continuous service as a Director until such vesting date. Read SEC document |
| July 25, 2022 Filed Jul 26, 2022 17:00 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | SaleCommon Stock | 2,020 | $2.22 | $4,479.15 |
DisclosureSEC source: 0001209191-22-043216 · doc4.xml · nonDerivative · entry 1 Samar Michael P. · CIK 0001775910 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,228 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person and represents shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.14 to $2.25, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within. F3 · balance_after: Includes 2,500 shares acquired under the Assembly Biosciences, Inc. Amended and Restated 2018 Employee Stock Purchase Plan on May 13, 2022. Read SEC document |
| June 24, 2022 Filed Jun 27, 2022 17:40 UTC | Unity Biotechnology, Inc. UBX · Entity 77428 | GrantStock Option (Right to Buy) · Derivative | 2,055 | $0.00 Strike: $0.59 | $0.00 |
DisclosureSEC source: 0000899243-22-024212 · doc4.xml · derivative · entry 1 Samar Michael P. · CIK 0001775910 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,055 Underlying: Common Stock · 2,055 shares Expires 2032-06-23 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the one-year anniversary measured from June 24, 2022 or (ii) the date of the 2023 Annual Meeting of the Issuer's stockholders, assuming continuous service as a Director until such vesting date. Read SEC document |
| May 25, 2022 Filed May 26, 2022 17:19 UTC | Unity Biotechnology, Inc. UBX · Entity 77428 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $0.76 | $0.00 |
DisclosureSEC source: 0000899243-22-019773 · doc4.xml · derivative · entry 1 Samar Michael P. · CIK 0001775910 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2032-05-24 F1 · derivative.exercise_date: Shares subject to the stock option vest and become exercisable in successive, equal monthly installments over a 36-month period commencing on May 25, 2022 (the "Vesting Commencement Date"), so that 100% of the shares become fully vested and exercisable on the third anniversary of the Vesting Commencement Date, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
| March 30, 2022 Filed Mar 31, 2022 16:52 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | SaleCommon Stock | 2,285 | $2.17 | $4,952.51 |
DisclosureSEC source: 0001209191-22-021781 · doc4.xml · nonDerivative · entry 2 Samar Michael P. · CIK 0001775910 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,748 F3 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person and represents shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.10 to $2.25, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within. Read SEC document |
| March 29, 2022 Filed Mar 31, 2022 16:52 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | GrantPerformance-based Restricted Stock Units · Derivative | 26,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-021781 · doc4.xml · derivative · entry 4 Samar Michael P. · CIK 0001775910 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,250 Underlying: Common Stock · 26,250 shares Expires 2027-03-29 F6 · derivative.exercise_price: Each performance-based restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. The shares are earned if either of two trading price metrics are met (each a "Stock Metric") either on or before the second or on or before the fourth anniversary of the grant date, as applicable. If a Stock Metric is met on or before the first anniversary of the grant date, then 50% of the RSUs vest on the first anniversary of the grant date and the remainder will vest on the second anniversary of the grant date. If a Stock Metric is achieved after the first anniversary of the grant date and on or before the fourth anniversary of the grant date, then 50% of the RSUs vest on the date that the Stock Metric is achieved and the remaining 50% of the RSUs vest on the first anniversary of the initial vesting date. Special vesting provisions apply in the case of a change in control transaction. F6 · derivative.exercise_date: Each performance-based restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. The shares are earned if either of two trading price metrics are met (each a "Stock Metric") either on or before the second or on or before the fourth anniversary of the grant date, as applicable. If a Stock Metric is met on or before the first anniversary of the grant date, then 50% of the RSUs vest on the first anniversary of the grant date and the remainder will vest on the second anniversary of the grant date. If a Stock Metric is achieved after the first anniversary of the grant date and on or before the fourth anniversary of the grant date, then 50% of the RSUs vest on the date that the Stock Metric is achieved and the remaining 50% of the RSUs vest on the first anniversary of the initial vesting date. Special vesting provisions apply in the case of a change in control transaction. Read SEC document |
| March 29, 2022 Filed Mar 31, 2022 16:52 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | GrantStock Option (right to buy) · Derivative | 105,000 | $0.00 Strike: $2.30 | $0.00 |
DisclosureSEC source: 0001209191-22-021781 · doc4.xml · derivative · entry 3 Samar Michael P. · CIK 0001775910 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,000 Underlying: Common Stock · 105,000 shares Expires 2032-03-29 F5 · derivative.exercise_date: Grant of stock options. The stock options vest over four years, assuming continuous service on each vesting date, as follows: 25% vest on the first anniversary of the date of grant, March 29, 2023; and the remaining 75% vest in 36 approximately equal monthly installments, with the options becoming fully vested on March 29, 2026. Read SEC document |
| March 29, 2022 Filed Mar 31, 2022 16:52 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | GrantCommon Stock | 26,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-021781 · doc4.xml · nonDerivative · entry 1 Samar Michael P. · CIK 0001775910 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,033 F1 · shares: Grant of restricted stock units. The restricted stock units vest in four equal installments, assuming continuous service on each vesting date, as follows: March 29, 2023; March 29, 2024; March 29, 2025; and March 29, 2026. F2 · balance_after: Includes 1,000 shares acquired under the Assembly Biosciences, Inc. 2018 Employee Stock Purchase Plan on November 14, 2021. Read SEC document |
| July 22, 2021 Filed Jul 22, 2021 17:52 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | GrantCommon Stock | 10,938 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-047818 · doc4.xml · nonDerivative · entry 1 Samar Michael P. · CIK 0001775910 · SVP, Fin. & Bus. Ops, PFO, PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,783 F1 · shares: Grant of restricted stock units. The restricted stock units vest in two equal installments, assuming continuous service on each vesting date, as follows: July 22, 2022 and July 22, 2023. Read SEC document |
| October 01, 2019 Filed Oct 1, 2019 18:32 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | GrantStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $9.31 | $0.00 |
DisclosureSEC source: 0001209191-19-051378 · doc4.xml · derivative · entry 2 Samar Michael P. · CIK 0001775910 · SVP, Finance and Bus. Ops, PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2029-10-01 F3 · derivative.exercise_date: Grant of stock options. The stock options vest over four years, assuming continuous service on each vesting date, as follows: 25% shall vest on the first anniversary of the date of grant, October 1, 2020; and the remaining 75% shall vest in 36 approximately equal monthly installments, with the options becoming fully vested on October 1, 2023. Read SEC document |
| October 01, 2019 Filed Oct 1, 2019 18:32 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | GrantCommon Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-051378 · doc4.xml · nonDerivative · entry 1 Samar Michael P. · CIK 0001775910 · SVP, Finance and Bus. Ops, PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,327 F1 · shares: Grant of restricted stock units. The restricted stock units vest in four equal installments, assuming continuous service on each vesting date, as follows: October 1, 2020; October 1, 2021; October 1, 2022; and October 1, 2023. F2 · balance_after: Includes 827 shares acquired under the Assembly Biosciences, Inc. 2018 Employee Stock Purchase Plan on May 14, 2019. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.